Novadaq Technologies Inc.  

(Public, TSE:NDQ)   Watch this stock  
Find more results for NDQ
15.78
-0.16 (-1.00%)
Sep 23 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 15.66 - 15.78
52 week 10.81 - 20.40
Open 15.66
Vol / Avg. 1,850.00/1,736.00
Mkt cap 895.60M
P/E     -
Div/yield     -
EPS -0.83
Shares 57.44M
Beta 0.57
Inst. own     -
Oct 26, 2016
Q3 2016 Novadaq Technologies Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Novadaq Technologies Inc at Morgan Stanley Global Healthcare Conference
Aug 17, 2016
Novadaq Technologies Inc at Wedbush PacGrow Healthcare Conference
Aug 10, 2016
Novadaq Technologies Inc at Canaccord Genuity Growth Conference - Webcast
Jul 27, 2016
Q2 2016 Novadaq Technologies Inc Earnings Call
Jul 27, 2016
Q2 2016 Novadaq Technologies Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -82.20% -48.31%
Operating margin -82.44% -56.47%
EBITD margin - -45.74%
Return on average assets -40.67% -16.54%
Return on average equity -45.47% -20.19%
Employees 56 -
CDP Score - -

Address

5090 Explorer Dr Suite 202
MISSISSAUGA, ON L4W 4T9
Canada
+1-905-6293822 (Phone)
+1-905-6290282 (Fax)

Website links

Description

Novadaq Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company's segment is medical devices. The Company's SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The Company's products include SPY, SPY Elite, LUNA and PINPOINT Imaging Systems, SPY Analysis Toolkit, DermACELL and SPY-Q Case Manager. DermACELL is an Acellular Dermal Matrix (ADM) that is used in breast reconstruction surgeries, as well as in the treatment of diabetic foot and venous stasis ulcers, and chronic non-healing wounds.

Officers and directors

Rick Mangat Ph.D. President, Chief Executive Officer
Roger Deck Chief Financial Officer
Anthony F. Griffiths Independent Non-Executive Chairman of the Board
Age: 85
Karen A. Licitra Director
Patrice E. Merrin Director
Age: 66
Robert S. White Director
Age: 54
Aaron Davidson Independent Director
Age: 46